You are here

ESC

ESC: AstraZeneca's SGLT2 med Farxiga flips script on competitors with 26% CV risk cut

ESC: AstraZeneca's SGLT2 med Farxiga flips script on competitors with 26% CV risk cut

Fierce Pharma

Flag link:

ESC 2019 – Amarin hopes for guideline boost despite regulatory delay

ESC 2019 – Amarin hopes for guideline boost despite regulatory delay

EP Vantage

European Society of Cardiology

Flag link:

MedCo's PCSK9 challenger steals the show at ESC with winning data

MedCo's PCSK9 challenger steals the show at ESC with winning data

Fierce Pharma

Medicines Company

PCSK9 inhibitors

European Society of Cardiology

Flag link:

ESC: Novartis looks for the bright side in flopped Entresto heart failure study

ESC: Novartis looks for the bright side in flopped Entresto heart failure study

Fierce Pharma

clinical trials

European Society of Cardiology

Flag link:

ESC: New Pfizer, BMS real-world data could boost Eliquis in Europe

ESC: New Pfizer, BMS real-world data could boost Eliquis in Europe

Fierce Pharma

Bristol-Myers Squibb

European Society of Cardiology

Flag link:

ESC 2018 preview – A possible boost for Abbott, and balloons go up against stents

ESC 2018 preview – A possible boost for Abbott, and balloons go up against stents

EP Vantage

Flag link: